New experimental evidence collected from rats shows that alpha-synuclein — the protein that causes Parkinson’s disease — can travel from the intestines to other organs, such as the heart and brain. These findings, reported in the study “Evidence for bidirectional and trans-synaptic parasympathetic and sympathetic…

A Phase 1b clinical trial exploring the oral LRRK2 inhibitor DNL151 has started dosing Parkinson’s patients, the therapy’s developer Denali Therapeutics announced. The 28-day, multicenter, and double-blind study (NCT04056689) is testing two doses of DNL151 against placebo in people with mild to moderate Parkinson’s disease, and with or…

Mutations in the SNCA and CTSB genes — among the many known to increase the likelihood of Parkinson’s disease — also contribute to the risk associated with mutations in the GBA gene, one of this disease’s most common and significant genetic risk factors, a study shows. Its results further…

High levels of corticosterone — a hormone that regulates energy, immune, and stress responses — is a risk factor for the development and progression of Parkinson’s disease, according to a mouse study. The study, “Chronic corticosterone aggravates behavioural and neuronal symptomatology in a mouse model of alpha-synuclein…

Alpha-synuclein in saliva may be a potential biomarker for Parkinson’s disease, according to a recent review article, but more research is necessary to determine its reliability as a possible screening approach. The study with that finding, “Salivary alpha‑synuclein as a biomarker for Parkinson’s disease: a systematic review,” was…

Scientist Wenquan Zou, MD, PhD, has received a two-year grant to develop a non-invasive skin test for diagnosing Parkinson’s disease, Alzheimer’s disease, and other neurodegenerative disorders. Diagnosing these disorders currently requires invasive analysis, either by imaging brain tissue or analyzing the cerebrospinal fluid (CSF) — the…

Women with advanced Parkinson’s disease who are homebound are more likely to live alone and may face greater barriers to accessing support. That finding comes from the study, “Sex-related differences in homebound advanced Parkinson’s disease patients,” which was published in Clinical Interventions in Aging. Parkinson’s motor…

Contrary to current knowledge, alpha-synuclein protein — whose toxic form is responsible for the formation of Lewy bodies — may play a crucial role in preventing cell death by repairing damaged DNA, a study has found. This critical function of the protein may also be lost in Parkinson’s patients, its…

A molecule called GM1 ganglioside may protect the brain against the molecular changes associated with Parkinson’s disease progression, and may one day directly treat its neurodegenerative processes, according to an early study. The study, “GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of…

Oxidative stress may be a trigger for Parkinson’s and can promote its progression by facilitating the spread of toxic alpha-synuclein protein across cells, researchers report. Their study, “Oxidative stress in vagal neurons promotes parkinsonian pathology and intercellular α-synuclein transfer,” was published in the Journal of Clinical Investigation. Parkinson’s is…